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Abstract
Uncertainty persists about risk factors for community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections
in Europe and the long-term efﬁcacy of decolonization strategies. To evaluate risk factors for CA-MRSA in Geneva, Switzerland, a hospital-
based, retrospective case–control study of 26 patients with CA-MRSA infection and 60 control patients was performed. To evaluate the
long-term effect of a systematic decolonization strategy (with and without concomitant systemic antibiotic therapy) for CA-MRSA patients,
a prospective cohort study of 79 patients with Panton–Valentine leukocidin-producing CA-MRSA isolates was conducted. Nationality other
than European Union or Swiss (adjusted OR 6.09; 95% CI 1.07–34.65) and absence of healthcare contact (adjusted OR 0.11, 95% CI
0.02–0.59) were independent predictors of CA-MRSA infection. Forty-ﬁve cases were followed (median, 22 months) to assess the
long-term efﬁcacy of the decolonization strategy; 39/45 (86.7%) had no clinical relapse and were MRSA-negative at their last follow-up,
whereas six remained MRSA-positive. Five of these six cases belonged to a family cluster. Decolonization rates were similar between
infected patients and asymptomatic carriers (92.6% vs. 77.8%, p = 0.20). This study shows a lack of readily modiﬁable risk factors for
CA-MRSA infection in this population, and suggests the potential usefulness of conducting decolonization procedures in a setting with
sporadic CA-MRSA infection. Further studies are needed to elucidate the role of migration as a factor contributing to the emergence of
CA-MRSA in Europe.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is an emerg-
ing community pathogen. Outbreaks of community-associated
MRSA (CA-MRSA) infections in otherwise healthy children
and adults have been described worldwide, manifesting mainly
as skin and soft tissue infections, but occasionally as invasive
disease [1,2]. CA-MRSA may produce Panton–Valentine leuko-
cidin (PVL) and other exotoxins [3]. In Geneva, PVL-producing
CA-MRSA was ﬁrst reported in 2002 [4]. A few months later,
the public health authority (Directorate General of Health)
established a CA-MRSA surveillance system in the Canton of
Geneva to ensure optimal case investigation and develop pre-
ventive strategies [5].
Numerous risk factors have been associated with CA-
MRSA infection. However, these may vary from one commu-
nity to another. Although recently published studies indicate
that the number of CA-MRSA infections in Europe is increas-
ing [6–9], few, if any, have assessed the risk factors for
CA-MRSA acquisition in this region [10–12]. Awareness of
trends in the epidemiology of CA-MRSA and risk proﬁling of
patients more likely to acquire CA-MRSA infections may
inﬂuence public health interventions and patient care.
Furthermore, there is ongoing controversy about the use
of topical decolonization for CA-MRSA carriers, as uncer-
tainty exists about long-term carriage and the efﬁciency of
eradication strategies. Current North American guidelines
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recommend neither contact tracing nor systematic decon-
tamination [13]. In this context, the objectives of our work
were therefore: (i) to assess risk factors for CA-MRSA infec-
tion in our region; and (ii) to evaluate the long-term effect of
a systematic decolonization strategy for CA-MRSA patients.
Materials and Methods
Setting and design
To meet these objectives, two separate epidemiological stud-
ies were conducted. To identify risk factors for CA-MRSA
infection among patients seen at our institution, we per-
formed a hospital-based, retrospective case–control study
(hereafter called ‘case–control study’). To assess long-term
carriage and the rate of microbiological eradication after top-
ical decolonization procedures (with and without concomi-
tant systemic antibiotic therapy), we performed a follow-up
study among individuals colonized or infected with any type
of PVL-positive CA-MRSA isolate (hereafter called ‘follow-up
study’). Both studies were initiated and conducted, in collab-
oration with local health authorities, at the University of
Geneva Hospitals (HUG), Switzerland, a 2200-bed, university
hospital that provides primary and tertiary care to the
Geneva region.
Study populations
We selected two different (but not mutually exclusive)
patient populations for the purpose of the two studies.
Cases for the case–control study were patients identiﬁed as
being clinically infected with CA-MRSA since the initiation of
the prospective CA-MRSA surveillance program in 2002 [5].
For the purpose of this surveillance system, a CA-MRSA iso-
late was deﬁned as any MRSA isolate with an antibiotic resis-
tance proﬁle and genotype different from those of the
endemic strain prevailing in the Geneva healthcare settings
(i.e. resistance to b-lactams, aminoglycosides, quinolones,
lincosamides and macrolides, and staphylococcal cassette
chromosome mec (SCCmec) type I, ST228, respectively),
diagnosed in a patient without history of hospitalization in
the previous 12 months [5].
For the follow-up study, cases were deﬁned as patients
infected or colonized with PVL-positive CA-MRSA seen at
HUG between September 1999 and December 2006.
Cases were identiﬁed because they presented with a clinical
isolate or were screened for infection control purposes (i.e.
contact tracing of room-mates of MRSA-infected or
colonized patients). If a patient was admitted more than
once, only the ﬁrst MRSA isolate was included in this
analysis.
Case–control study
For the case–control study, a case was deﬁned as any patient
clinically infected with microbiologically documented CA-
MRSA seen at HUG (inpatient and outpatient care) between
January 2002 and March 2006. Cases with a history
of healthcare-associated MRSA infection (onset ‡48 h after
hospital admission) and infections due to the prevailing hos-
pital-associated MRSA strain in the Geneva hospital settings
were excluded. In cases of clustering, only the index case
was selected.
For each CA-MRSA case eligible for the study, at least
one and up to ﬁve controls from the same patient-care area
at HUG were randomly selected from the admission roster.
Eligible controls were excluded if they were known MRSA
carriers. The selection of control patients was conducted
retrospectively using a random letter generator.
Data collection
A questionnaire was developed that covered a range of char-
acteristics, including demographic factors (age, sex, national-
ity and place of residence, and prior stay in a collective
housing facility), comorbidities, occupation, household
members (number, occupation, presence of children, and
health history), exposure within the preceding 12 months to
medical care, antibiotic therapy or invasive procedures,
leisure activities (sauna, ﬁtness centre and contact sports),
and foreign travel (with/without healthcare contact abroad).
The questionnaire was sent to the physician in charge of
case patients, requesting demographic and clinical informa-
tion for the 12-month period preceding the diagnosis. This
questionnaire was ﬁlled in by the physician, with the assis-
tance of the patient when deemed necessary. Controls
received the questionnaire by mail, with a cover letter and a
stamped return envelope. A follow-up telephone call was
made 2 weeks after the letters were sent, to increase the
response rate. An anonymous database for storage of all epi-
demiological, clinical and laboratory data was created in
Excel. Ethical approval for the study was obtained from the
review board of the Geneva Physicians Association.
Follow-up study
To evaluate the long-term efﬁcacy of the CA-MRSA decolo-
nization protocol in terms of clinical relapse and microbio-
logical eradication, we included all patients identiﬁed at HUG
as being either colonized or infected by PVL-positive CA-
MRSA during a 7-year period. Cases were identiﬁed through
the electronic data ﬁles of the Clinical Microbiology Labora-
tory at HUG and prospective surveillance data collected
since 2002. However, demographic data, such as the type of
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residence or travel history, were available only from April
2003 onwards. At baseline, all patients received topical treat-
ment with twice-daily nasal mupirocin and daily 4% chlorhex-
idine showers for 10 days. Concomitantly, patients
presenting with overt infection were treated with systemic
antibiotics as selected by the attending physician (trimetho-
prim–sulphamethoxazole or clindamycin). Digestive tract
decontamination was not carried out. In cases of familial
clustering, treatment was extended to the entire family,
regardless of CA-MRSA status. Recommended environmental
decontamination measures included frequent linen changes
and the use of dedicated personal hygiene products such as
facecloths, as described in our local guidelines (available on
request at stephan.harbarth@hcuge.ch).
For follow-up, patients were reached by telephone and
invited to submit samples for detection of CA-MRSA car-
riage. Samples were collected at a follow-up visit at the
outpatient clinic or at a visit to the patient’s home.
Screening was conducted by sampling of the anterior nares
and perineal region, and other sites (skin lesions, urine,
and sputum) when clinically indicated. Specimens were col-
lected with a sterile Dacron-tipped swab premoistened
with sterile saline solution. Microbiological eradication was
deﬁned as the absence of CA-MRSA in any of the clinical
specimens obtained at least 1 month after initial presenta-
tion.
Microbiological methods
All isolates collected from case patients of the two studies
were stored and analysed at the clinical microbiology labora-
tory at HUG. Presumptive identiﬁcation of S. aureus was per-
formed with ORSA plates (Oxoid, Basingstoke, UK) and
Pastorex agglutination (BioRad, Reinach, Switzerland). The
antimicrobial susceptibility proﬁle was determined with Vitek
2 cards for Gram-positives (bioMe´rieux, Marcy l’Etoile,
France) according to CLSI guidelines. The SCCmec element
and PVL gene were detected and characterized with a previ-
ously described quantitative PCR essay [14].
Comparison of CA-MRSA using multilocus variable-number
tandem repeat analysis (MLVA)
To assess the diversity of CA-MRSA isolates in our popula-
tion, we compared isolates of 23 clustered cases included in
the follow-up study. A previously published method was used
to evaluate the genomic content of these isolates [15,16].
Brieﬂy, this assay is based on a multiplex PCR using nine
primer pairs targeting genes showing variable numbers of
tandem repeats. An additional pair of primers allows ampliﬁ-
cation of the mecA gene. This method shows discriminatory
power that is at least similar to that of pulsed-ﬁeld gel
electrophoresis [15]. The analysis was performed on isolated
colonies grown on Mueller–Hinton agar disrupted by vortex
agitation [15]. PCR ampliﬁcation was then evaluated using
a microcapillary electrophoresis system (BioAnalyzer; Agi-
lent, Technologies, Palo Alto, CA, USA), and automatically
analysed using speciﬁcally developed software [15].
Statistical analysis
For the case–control study, conditional univariate and mul-
tivariate logistic regression models were used to estimate
ORs and the associated 95% CIs. Categorical variables
were compared by chi-square test when appropriate. Con-
tinuous variables were converted to categorical variables
when they did not fulﬁl criteria of linearity. p-Values less
than 0.05 were considered to be statistically signiﬁcant.
Cases and controls were matched by patient-care area. All
covariates that were found to be signiﬁcantly associated
(p <0.05) with CA-MRSA infection in the univariate analysis
were included in a multivariable model. The variables were
entered simultaneously into the model to determine the
adjusted associations between these covariates and
CA-MRSA infection. For the follow-up study, characteristics
of patients with successful vs. failed CA-MRSA decoloniza-
tion were compared. All data were stored in an Excel
database (Microsoft Corp, Redmond, WA, USA); STATA
9.0 software (STATA Corp., College Station, TX, USA)
was used for all analyses.
Results
Case–control study
We enrolled 26 patients with newly diagnosed CA-MRSA
infection and 60 controls (average ratio, 1 : 2.3). The
response rate for potential controls was 44.4% (60/135). For
one case, no control patient could be identiﬁed. The clinical
features of cases and controls are given in Table 1. Cases
and controls did not differ signiﬁcantly in sex, age, profes-
sion, presence of comorbidity, or recent use of antibiotics.
Sport activities (practice of contact sports or attendance at
a ﬁtness centre in the preceding 12 months) and pastimes
(travel outside Switzerland and use of saunas) were not
associated with CA-MRSA infection. Nationalities other than
European Union or Swiss (OR 7.69; 95% CI 1.62–36.45)
and recent stay in a collective housing facility (OR 8.95;
95% CI 1.02–78.29) were signiﬁcantly associated with
CA-MRSA infection. CA-MRSA-infected patients were also
signiﬁcantly less likely than controls to have consulted a
healthcare professional in ambulatory care in the preceding
12 months (OR 0.12; 95% CI 0.03–0.59).
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Three variables were eligible for inclusion in the
multivariable model. In this model (Table 2), nationality other
than European Union or Swiss (adjusted OR 6.09; 95% CI
1.07–34.65) and absence of healthcare professional consulta-
tion (adjusted OR 0.11; 95% CI 0.02–0.59) were
independently associated with CA-MRSA infection. Recent
stay in collective housing, although signiﬁcant in bivariate
analysis, was not a statistically signiﬁcant predictor of
CA-MRSA infection in the multivariable model.
Follow-up study
The demographic and clinical characteristics of PVL-positive,
CA-MRSA cases are given in Table 3. Of 79 cases with PVL-
positive CA-MRSA detected, 59.5% had skin infection, and
36.7% were asymptomatic carriers. Nine clusters represent-
ing 23 patients were observed, and 70.8% were sporadic
cases. Most isolates (92.4%) had an SCCmec type IV cassette
element.
Forty-ﬁve (57.0%) cases had microbiological and clinical
follow-up (median, 22 months); 39/45 (86.7%) had no clinical
relapse and were MRSA-negative at their last follow-up, and
six remained MRSA-positive. Five of these six cases belonged
to a particular family cluster (follow-up, 49 months). Multilo-
cus sequence typing of the persistent carriers’ strains
TABLE 1. Characteristics of pati-







controls (%) OR 95% CI p
Demographics
n 26 60
Gender (male) 16 (61.5) 25 (41.7) 2.34 0.83–6.62 0.11
Age (£25 years) 8 (30.8) 10 (16.9)a 2.83 0.75–10.6 0.12
Place of residence (Geneva) 13 (50.0) 44 (73.3) 0.42 0.17–1.03 0.06
Citizenship other than Swiss/European
Union
9 (34.6) 4 (6.8)a 7.69 1.62–36.45 0.01
Stay in collective housingb 5 (20.8)c 1 (1.7%)a 8.95 1.02–78.29 0.048
Employment
Manual worker 7 (26.9) 9 (15.0) 2.81 0.69–11.42 0.15
Ofﬁce worker 4 (15.4) 17 (28.3) 0.57 0.17–1.91 0.37
Healthcare professional 1 (3.8) 2 (3.3) 1.30 0.12–14.51 0.83
Student 2 (7.7) 6 (10.0) 0.69 0.13–3.73 0.67
None/retired 8 (30.8) 14 (23.3) 1.26 0.40–3.97 0.69
Other 1 (3.8) 5 (8.3) 0.36 0.04–3.19 0.36
Unknown 3 (11.5) 7 (11.7) 1.07 0.26–4.46 0.92
Health history
Presence of any comorbidityd 8 (30.8) 28 (47.5)a 0.33 0.10–1.04 0.06
Dermatological condition 1 (3.8) 5 (8.6)e 0.34 0.03–3.32 0.35
Diabetes 2 (7.7) 3 (5.1)a 1.46 0.23–9.13 0.68
Recent use of antibioticsc 10 (47.6)f 20 (36.4)g 1.39 0.51–3.80 0.52
Exposure to ambulatory careh 17 (65.4) 54 (91.5)a 0.12 0.03–0.59 0.009
Household members
Hospitalization 4 (16.7)c 23 (38.3) 0.28 0.07–1.02 0.054
Healthcare professional 2 (8.7)i 10 (17.2)e 0.50 0.10–2.41 0.39
Dermatological condition 4 (17.4)i 6 (10.9)g 1.49 0.36–6.12 0.58
Presence of ‡1 child 18 (69.2) 27 (45.0) 3.02 0.86–10.61 0.08
Activities
Travel 19 (79.2%)c 46 (78.0)a 1.03 0.32–3.32 0.96
Sauna 1 (4.2)c 7 (13.2)j 0.37 0.04–3.18 0.37
Fitness centre 1 (4.2)c 14 (25.0)k 0.16 0.02–1.33 0.09
Contact sports 2 (8.3)c 4 (7.5)j 1.26 0.20–8.03 0.81
an = 59 (one case missing).
bStay in asylum seekers’ reception centre, prison or military barracks in the preceding 12 months.
cn = 24 (two cases missing).
dIncludes any chronic pulmonary, cardiac, dermatological, endocrine, renal or neurological condition, cancer, human
immunodeﬁciency virus infection, and use of immunosuppressants.
en = 58 (two cases missing).
fn = 21 (ﬁve cases missing).
gn = 55 (ﬁve cases missing).
hIn the preceding 12 months.
in = 23 (three cases missing).
jn = 53 (seven cases missing).
kn = 56 (four cases missing).
TABLE 2. Multivariate conditional regression analysis of risk
factors for community-associated methicillin-resistant
Staphylococcus aureus infection, matched case–control study
(cases, 26; controls, 60)
Explanatory variable OR 95% CI p
Citizenship other than Swiss/European
Union
6.09 1.07–34.65 0.042
Stay in collective housinga 16.08 0.60–430.33 0.098
Exposure to ambulatory careb 0.11 0.02–0.59 0.01
Log likelihood value of the model = )17.8.
aStay in asylum seekers’ reception centre, prison or military barracks in the pre-
ceding 12 months.
bIn the preceding 12 months.
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revealed ST80 for the family cluster and ST30 for the lone
case. Decolonization rates were similar between infected
patients and asymptomatic carriers (92.6% vs. 77.8%,
p = 0.20). All persistently colonized cases had either clinical
relapse or a symptomatic relative.
Genotyping of CA-MRSA
Altogether, 23 CA-MRSA isolates (one isolate per patient),
representing nine different clusters, were assessed by
MLVA (Fig. 1). With the use of a cut-off value of >80%
relatedness between BioAnalyzer proﬁles, seven different
MLVA genotypes were identiﬁed. The most important clus-
ter was composed of ten ST80-MRSA-IV isolates, but the
analysis revealed an important diversity of genetic back-
grounds in this population. Three smaller family clusters
had clonally related strains (ST5-MRSA-IV, ST59-MRSA-V,
and ST30-MRSA-IV). Interestingly, in two instances, family
members had clonally different strains.
Discussion
This study showed that in this population from Geneva, Swit-
zerland, there was no readily identiﬁable risk factor for CA-
MRSA infection that was amenable to a simple intervention.
However, our ﬁndings suggest the potential usefulness of
TABLE 3. Demographic charac-
teristics, type of infection and










Number of cases 79 45 (57.0%) 34 (43.0%) –
Mean age (years, SD) 32 ± 21 29 ± 21 35 ± 21 0.27
Male gender 41 (51.9%) 17 (37.8%) 24 (70.6%) 0.004
Absence of comorbidity 57 (72.2%) 32 (71.1%) 25 (73.5%) 0.81
Stay in collective housinga,b 5 (13.2%)c 5 (19.2%) 0 (0.0%) 0.10
Previous antibiotic exposureb 6 (27.3%)d 4 (25.0%) 2 (33.0%) 0.70
Travel outside Switzerlandb 31 (77.5%)e 21 (75.0%) 10 (83.3%) 0.56
Type of infection/colonization
Primary cutaneous abscess or
pyoderma
47 (59.5%) 26 (57.8%) 21 (61.8%) 0.72
Other infectionf 3 (3.8%) 1 (2.2%) 2 (5.9%) 0.39
Colonization only 29 (36.7%) 18 (40.0%) 11 (32.4%) 0.49
SD, standard deviation.
Data are expressed as number and percentage, unless indicated otherwise.
aPrison, nursing home, or asylum seeker camp.
bData available from April 2003 onwards.
cNo. of observations, 38; 41 observations missing.
dNo. of observations, 22; 57 observations missing.
eNo. of observations, 40; 39 observations missing.
fIncludes one central venous catheter exit site infection, one catheter-associated urinary tract infection, and one case
of neonatal dacryocystitis.
0.5 0.4 0.3 0.2 0.1 0
FIG. 1. Cluster analysis of 23 commu-
nity-associated methicillin-resistant
Staphylococcus aureus isolates based on
multilocus variable-number tandem
repeat analysis (MLVA). Each strain rep-
resents one unique patient. With the
use of a cut-off value of >80% related-
ness between BioAnalyzer proﬁles, dif-
ferent MLVA genotypes were identiﬁed.
Members of the same cluster have the
same number, and the letters represent
patients’ initials.
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conducting decolonization procedures in a setting with spo-
radic CA-MRSA infection.
In our community, patients of non-European origin appear
to be at risk for CA-MRSA infection. This ﬁnding is consis-
tent with those of other studies from Europe. A recently
published case-series from Barcelona, Spain identiﬁed an
emerging CA-MRSA problem among immigrants from South
America [17]. A case–control study from Denmark found an
association between foreign ethnicity and CA-MRSA infection
(Bo¨cher et al. [18]). Maier et al. [19] have also found, in a
case-series, a large proportion of cases of CA-MRSA infec-
tion associated with travel and migration in Bavaria, Ger-
many. The role of migration as a non-negligible cause of CA-
MRSA dissemination was also supported by two molecular
epidemiological studies conducted in Switzerland [20,21].
We have to emphasize, however, that CA-MRSA is not con-
ﬁned to speciﬁc socio-economic classes, and can affect all
types of migrants, from foreign-born prison inmates to top-
level diplomats and wealthy patients [22]. Clearly, further
studies are needed to elucidate the role of migration as a
potential factor contributing to the emergence of CA-MRSA
in Europe.
Although a cause-and-effect relationship cannot be
inferred from our study, this study showed that CA-MRSA
carriers have less medical contact than controls in our
region. In contrast, other factors identiﬁed in studies con-
ducted mainly in the USA, such as comorbidity [23], age
[23], sexual preference [24], previous antibiotic use [12],
having a relative who works in a healthcare setting [25], stay
in a closed collective housing facility [25,26], and practising
contact sports [27,28], were not shown to be associated
with CA-MRSA infections in Geneva. Although this may be
due to the small size of our study and lack of statistical
power, it may also reﬂect true differences in the epidemiol-
ogy of CA-MRSA infection in different settings.
CA-MRSA is not endemic in Geneva. On the other
hand, this city is a notoriously multicultural one, with 38%
of its 445 000 inhabitants being of foreign origin (including
European Union citizens) [29]. The Geneva region is home
to a multitude of international organizations. We have pre-
viously shown that CA-MRSA strains in Geneva have a
high degree of molecular diversity [10,21], another ﬁnding
of this study. It can be hypothesized that new strains of
CA-MRSA are continuously being introduced in Geneva by
the migratory ﬂow and travel-associated activities [30].
Thus, constant vigilance, intensive contact tracing and
decolonization of carriers appear to be indicated to limit
the spread within the community.
To our knowledge, no previous published investigation has
assessed the long-term efﬁcacy of CA-MRSA eradication
treatment. In our study, the majority of PVL-positive
CA-MRSA carriers subjected to a decolonization protocol
had cleared the pathogen upon follow-up. Even though the
relative contribution of the topical decolonization protocol
to MRSA eradication remains unknown in the absence of a
control group, these preliminary results suggest that the
procedure is safe and has a sustained effect over time. The
absence of clinical relapse in a patient and his or her family
predicted successful decolonization. Moreover, these results
suggest that decolonization strategies, combined with an
efﬁcient surveillance system, may help to limit the propaga-
tion of CA-MRSA within a large community, despite the
continuous inﬂux of transmissible strains. Even though
current US guidelines recommend neither contact tracing
nor systematic decontamination with topical regimens [13],
we believe these strategies could be effective in controlling
the spread of CA-MRSA, especially in settings with low
CA-MRSA prevalence. There is an urgent need for a ran-
domized trial to establish the optimal decolonization method
for CA-MRSA. A recent cluster-randomized, double-blind,
placebo-controlled trial investigating the efﬁcacy of intranasal
mupirocin therapy in soldiers to prevent CA-MRSA infection
showed that mupirocin was no more effective than placebo
in preventing infection within this population [31]. However,
the study might have been insufﬁciently powered, owing to
an unexpectedly low infection rate (7.7% vs. 38% in a previ-
ous report [32]).
The present study has clear limitations. First, recall bias,
one of the inherent potential limitations of case–control
studies, cannot be excluded. In fact, concerning cases’ ques-
tionnaires were ﬁlled out by treating physicians, whereas
controls answered the questionnaire themselves. This may
have played a role in the apparent lack of association with
some previously described risk factors. However, this is an
unlikely bias with regard to nationality. Second, the percent-
age of non-European Union people in the control group is
lower than in the general population of Geneva, suggesting
that a selection bias might have occurred. The fact that our
survey was in French might have contributed to the
under-representation of immigrants in the control group.
Moreover, some addresses of non-Swiss control patients
were incorrect or not up-to-date. On the other hand, the
relatively low proportion of migrants among the controls is
plausible, as healthy young immigrants are more unlikely to
be admitted to HUG. Third, as only the index case of a
cluster was included, this study was underpowered to assess
risk factors for local transmission of CA-MRSA. Therefore,
the study cannot establish where CA-MRSA acquisition
occurred. Furthermore, the unique demographics of
Geneva, the under-representation of the USA300 clone in
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our population, the relatively small sample size and the
selection of cases and controls from among those who
consulted at HUG rather than from the general population
might limit the generalizability of our ﬁndings to other
settings. Finally, in the absence of a comparator group in the
follow-up study, we cannot exclude the possibility that some
individuals may have spontaneously cleared CA-MRSA.
However, the potential implications of our ﬁndings are
underscored by the worldwide increase in the incidence of
CA-MRSA infections.
In summary, these results show a lack of readily modiﬁ-
able risk factors for CA-MRSA infection in Geneva, and
suggest that decolonization procedures could be useful in
preventing the spread of CA-MRSA in a non-endemic set-
ting. Despite some methodological limitations, this study,
together with other recently published ﬁndings, suggests
that migration may represent a non-negligible risk factor
contributing to the spread of CA-MRSA in Europe. Further
research is needed to assess the efﬁcacy of decolonization
strategies in communities in which CA-MRSA has already
become endemic.
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